Regorafenib in Hepatocellular Carcinoma
Regorafenib 160 mg orally once daily for 21 days of each 28-day cycle is the recommended second-line treatment for patients with advanced HCC who have progressed on sorafenib (≥400 mg/day for ≥20 days in the last 28 days), with Child-Pugh A liver function and ECOG performance status 0-1. 1
Patient Selection Criteria
Strict eligibility requirements must be met:
- Prior sorafenib tolerance: Patient must have tolerated sorafenib at ≥400 mg/day for at least 20 of the last 28 days before progression 2, 3
- Liver function: Child-Pugh class A only 1, 2
- Performance status: ECOG 0-1 1
- Disease progression: Documented radiographic progression on sorafenib 2, 3
Critical pitfall: Regorafenib should NOT be used in patients who discontinued sorafenib due to intolerance or toxicity, as the drugs have nearly identical molecular structures with similar toxicity profiles 4, 5. This is a common error in clinical practice.
Dosing Regimen
Standard dosing: 2
- 160 mg orally once daily
- Days 1-21 of each 28-day cycle
- Take after a low-fat meal
- Continue until disease progression or unacceptable toxicity
Dose reduction schedule for toxicity: 2
- First reduction: 120 mg daily
- Second reduction: 80 mg daily
- Discontinue if unable to tolerate 80 mg daily
Monitoring Requirements
Baseline assessment:
- Liver function tests (AST, ALT, bilirubin, alkaline phosphatase)
- Complete blood count
- Blood pressure
- Electrolytes (magnesium, potassium, calcium)
- Child-Pugh score confirmation
- ECOG performance status
During treatment: 2
- Liver function tests: Monitor before each cycle and as clinically indicated
- Blood pressure: Weekly for first 6 weeks, then before each cycle
- Hand-foot skin reaction assessment: At each visit
- Performance status: Before each cycle
Imaging for response:
- CT or MRI every 8 weeks using mRECIST criteria 2
Expected Efficacy
Based on the pivotal RESORCE trial 2, 3:
- Median overall survival: 10.6 months (vs 7.8 months with placebo)
- Median progression-free survival: 3.1 months (vs 1.5 months with placebo)
- Objective response rate: 11% (vs 4% with placebo)
- Disease control rate: 65%
Adverse Event Management
Most common grade 3-4 toxicities: 2, 3
- Hypertension (15%)
- Hand-foot skin reaction (13%)
- Fatigue (9%)
- Diarrhea (3%)
Management algorithm:
For Grade 2 toxicity:
- Continue treatment at reduced dose (120 mg daily)
For Grade 3 toxicity (first occurrence):
- Hold treatment until Grade ≤2
- Resume at 120 mg daily
For Grade 3 toxicity (second occurrence):
- Hold treatment until Grade ≤2
- Resume at 80 mg daily
For Grade 4 toxicity or persistent Grade 3:
- Permanently discontinue 2
Specific toxicity management:
- Hypertension: Hold for symptomatic Grade 2 or any Grade 3-4; resume at reduced dose once BP <140/90 mmHg 2
- Hemorrhage: Permanently discontinue for Grade 2+ requiring medical intervention 2
- Hepatotoxicity: Permanently discontinue for Grade 3+ ALT elevation or AST/ALT >3× ULN with bilirubin >2× ULN 2
Absolute Contraindications
Do NOT use regorafenib in: 6
- Child-Pugh B or C liver function (significantly worse outcomes: median OS 4.6 months vs 10.6 months in Child-Pugh A; higher Grade 3-4 adverse events: 27% vs 14%)
- Patients intolerant to sorafenib (unable to tolerate ≥400 mg/day for ≥20 days) 4, 5
- ECOG performance status ≥2
- Active gastrointestinal perforation or fistula 2
- Severe or uncontrolled hypertension 2
Special caution: Patients with ALBI grade 3 within Child-Pugh B have particularly poor outcomes and increased bilirubin toxicity—regorafenib is strongly discouraged 6.
Drug Interactions
Avoid concomitant use with: 2
- Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's wort)
- Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, grapefruit juice)
Monitor closely: BCRP substrates (methotrexate, rosuvastatin) for increased toxicity 2
Unexpected interaction: One case report documented lithium toxicity in a patient on chronic lithium therapy, suggesting a potential drug-drug interaction requiring close monitoring 7.
Predictors of Better Outcomes
Real-world data suggest better outcomes with: 8, 9
- Time to progression on sorafenib ≥ median (typically ≥3-4 months)
- AFP <400 ng/mL at regorafenib initiation
- Absence of macrovascular invasion
- Albumin >3.5 g/dL
- Lower NLR (neutrophil-to-lymphocyte ratio)
Surgical Considerations
Perioperative management: 2
- Hold regorafenib at least 2 weeks before elective surgery
- Do not resume for at least 2 weeks after major surgery
- Resume only after adequate wound healing confirmed